Search | Webyourself Social Media Platform

added article Health

2024-05-24 11:48:38 -

Cosentyx Drug (secukinumab): A Novel Biologic Therapy for Moderate to Severe Plaque Psoriasis

Cosentyx (secukinumab) is a human monoclonal antibody that selectively binds to and inhibits interleukin-17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in inflammatory and immune responses. Cosentyx was developed by Novartis Pharmaceuticals and was approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of moderate to severe plaque psoriasis in...

0 Comments 0 Shares 678 Views 0 Reviews